C5 and atypical hemolytic-uremic syndrome: The monoclonal antibody Eculizumab inhibits cleavage of C5 to C5a and C5b and is an effective treatment for patients with paroxysmal nocturnal haemoglobinuria (PNH) or atypical haemolytic uremic syndrome (aHUS) [44, 45].